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FLOW CYTOMETRIC AND DEMOGRAPHIC ANALYSIS OF  
T CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PAKISTANI 
POPULATION  
MR Khawaja, SS Allana, AN Akbarali, SN Adil, M. Khurshid, S Pervez 
Department of Pathology & Microbiology, The Aga Khan University, Karachi, Pakistan 
Background: This study was carried out to analyze the proportion of T cell acute lymphoblastic 
leukemia (TALL) among all acute lymphoblastic leukemia (ALL) in Pakistani population and its 
correlation with the demographic features. Accuracy of cell surface markers used in flow 
cytometric analysis of the leukemic cells was also determined. Methods: Data of 209 consecutive 
cases of acute lymphoblastic leukemia (ALL) presenting between July 1995 and July 2003 was 
analyzed. Flow cytometry was performed on all ALL cases using the standard protocols. TALL 
markers included CD3, CD5 and CD7. Results: Proportion of TALL among known ALL 
Pakistani patients was 17.22%. Mean age of the TALL patients was 17.2 years. Proportion of 
TALL was higher in adults than in children (21.95% vs. 14.17%). Overall in this study there were 
more male patients affected by TALL (25/36 or 69.40%) than females (11/36 or 30.60%). The 
female to male ratio among TALL patients was 1:2.27. However, the proportion (%) of TALL in 
females was higher than males (18.96% vs. 15.82 %) i, e, 1.2:1. CD7 was found to be the most 
sensitive among both adults & children. It was positive in 94.4% of the TALL cases. Conclusion: 
Proportion of TALL among ALL in Pakistan is similar to that reported in this region, indicating a 
candidate association with geographical location and socioeconomic status. The reactivity of 
markers with TALL cells was similar to what we expected based upon literature.  However, due to 
some aberrant and cross reactivity displayed by each marker, we strongly recommend a panel 
approach including B and myeloid markers to ensure a correct diagnosis of TALL. 
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INTRODUCTION 
The hallmark for the diagnosis of acute leukemia, 
until recent past, has been the morphology and 
cytochemistry. They provide correct diagnosis in 
about 80% of the cases. For instance, Jawaid et al. in 
their series reported that 11% cases of acute 
leukemias were unidentifiable in terms of their 
phenotype while 9% were identified incorrectly on 
morphological basis, all of which were correctly 
allocated to their lineages after flow cytometric 
analysis.1 Thus, major developments in the field of 
immunology have now brought an era of diagnosing 
acute leukemias by means of flow cytometry. Flow 
cytometry is a powerful tool for the investigation of 
normal and neoplastic cells and their classification at 
every level. Therefore, it has great prognostic and 
therapeutic implications. Its ability to measure 
multiple parameters on individual cells in a 
suspension at high speed is ideal for the study of 
leukemic cells.2 It identifies cell markers by applying 
monoclonal antibodies against them. The discovery 
of monoclonal antibodies has made it possible to 
define the precise stages of differentiation and 
lineage of hematopoietic cells and has resulted in 
tremendous advancement in the classification of 
leukemias.1-5 Not only acute myeloid leukemia 
(AML) can be differentiated from the acute 
lymphoblastic leukemia (ALL) but B-cell or T-cell 
lineages can also be determined in the latter (6), which 
cannot be achieved by morphology and 
cytochemistry alone. By this method more than 98% 
of acute leukemia cases can now be precisely 
allocated to their respective lineages (1). In addition to 
leukemia phenotyping leukemia associated 
phenotypic features have been used to detect minimal 
residual disease in both ALL and AML.1
Acute leukemia results from clonal 
proliferation of immature hematopoietic cells 
“frozen” at an early stage of differentiation2 including 
primitive cells with multilineage potential.7 ALL and 
AML are its two major types. ALL is broadly 
classified as having a T- or B-cell origin, with further 
division of B-lineage ALL into three distinct 
subtypes: early pre–B cell, pre–B cell, and B cell. A 
fourth subtype, transitional pre–B-cell ALL, was 
recently described and may be associated with a 
favorable prognosis.8 T-cell ALL has been 
subclassified according to the stage of thymocyte 
differentiation or the stage in the expression of T-
cell–receptor protein but this approach has limited 
clinical usefulness.8 Therefore, we have limited our 
discussion broadly to TALL without going into 
details of subclasses of TALL.   
Flow cytometric analysis of leukemic 
samples started routinely at The Aga Khan University 
(AKU), Department of Pathology in 1995. Since 
then, there has been continuous evaluation and 
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revision of the panel of antibodies used to analyze the 
leukemic cells. It is among the very few hospitals in 
Pakistan, which is endowed with the facility, as a 
major tertiary care referral center with its currently 
48 laboratory collection points in all four provinces 
of Pakistan. Thus, the samples studied at AKU 
Hospital are a good representative of overall 
Pakistani population.  
MATERIAL AND METHODS 
Details of the flow cytometric analysis of all the 
leukemic cases that appeared in The Aga Khan 
University Hospital between July 1995 and July 2003 
were obtained from the records of the Department of 
Pathology. Patients with Acute Lymphoblastic 
Leukemia were selected and further information was 
documented on specially designed data entry forms. 
The data was entered in SPSS 10.0 (Statistical 
Package For Social Sciences). Analysis was 
performed using the same software. Fischer’s Exact 
Test and Chi-Square Tests were performed to 
determine any possible associations between 
demographic parameters and expression of specific 
antigens on the TALL cells. P-Value of <0.05 was 
considered to be the criteria for significance. 
Flow cytometry was performed on all the 
peripheral blood and bone marrow samples by 
centrifuging mononuclear cells from them on Ficol. 
These were then stained with florescence labeled 
antibodies (obtained from Becton Dickinson, U.S.A) 
and run on FACSCAN using cell quest software. The 
same software was used to analyze the flow 
cytometry data. CD19, CD20, CD22, CD10, CD3, 
CD5, CD7, CD13, CD33 and HLA-DR were tested 
on all the cases. Positivity of a clone for a cell surface 
marker was accepted if more than 30% of the cells 
stained with the antibody for the respective marker.  
RESULTS 
Data from a total of 209 cases of acute lymphoblastic 
leukemia (ALL) was retrieved, out of which 127 
(60.80%) were children i.e. less than or equal to 15 
years and 82 (39.20%) were adults i.e. more than 15 
years (Table-1). Out of 209, 158 (75.60%) cases were 
males and 51 (24.40%) were females (Table1). Thus 
among ALL patients, adults to children ratio turned 
out to be 1:1.55 and female to male ratio turned out 
to be 1:3.1. The mean age of the ALL patients was 
calculated to be 14.85 years. 
The number of patients who were diagnosed 
to have TALL was 36. Thus the proportion of TALL 
among acute lymphoblastic leukemia in this study 
was 17.22%. The mean age of the patients was 17.2 
years with a standard deviation of 12.96. The age 
range of the sample was 44 years (the youngest 
patient aged 1 year and the oldest 45 years) with the 
median age of 15.0 years. Mean age among children 
was 7.0 years with the standard deviation of 3.6 and 
that among adults was 27.44 years with a standard 
deviation of 10.52. Though, equal number of children 
and adults suffered from TALL, proportion of TALL 
in patients suffering form ALL was higher in adults 
than in children (21.95% vs. 14.17%). Thus children 
to adults ratio of TALL cases in ALL patients was 
1:1.55. Figure-1 shows the number of TALL cases in 
different age groups. 
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Figure-1:Histogram representing the distribution 
of TALL among different age groups 
Overall in this study there were more male 
patients affected by TALL (25/36 or 69.40%) than 
females (11/36 or 30.60%) (Table-1). The female to 
male ratio among TALL patients was 1:2.27. 
However, proportion (%) of TALL in females was 
higher than males (18.96% vs. 15.82%) i,e,1.2:1 Of 
all the markers against which the monoclonal 
antibodies were directed (Figure-2), CD7 was found 
to be the most sensitive among both adults & children 
groups and male & female groups. It was positive in 
94.4% of the TALL cases (Table2). CD5 came out to 
be positive in 86.1% of the patients, which is a 
reasonable sensitivity already expected based on 
previous studies. CD3 was positive in 38.8% patients. 
Sensitivity of CD3 might not sound too impressive 
but it is justifiable by the fact that the samples used in 
our study were not permeabalised to expose the CD3 
antigen, which are primarily present in the cytoplasm. 
Data was also used to determine if there was any 
significant difference in the distribution of reactivity 
in two age and sex groups (Table-2). Except for the 
significant number of female TALL cases cross-
reacting with HLA-DR than male cases, distribution 
of reactivity was similar in both male-female and 
children-adult groups.   
As some cross-reactivity between TALL and 
myeloid markers is well known, a panel approach 
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was undertaken in all cases of leukemia phenotyping. 
This did show weak expression of two myeloid 
markers CD13 and CD33 on a small percentage of 
TALL cells (8.3% & 2.7% respectively). HLA-DR is 
also a useful marker as it is negative on a great 
majority of TALL cells while usually shows strong 
reactivity on BALL and myeloid leukemia cells. This 
does make sense, as normal T lymphocytes also don’t 
express HLA-DR on their surface. 
DISCUSSION 
ALL is diagnosed to 3000-4000 persons in US each 
year.7 About 13% of them are diagnosed as TALL (9). 
Recognition of TALL is also important in the sense 
of therapeutic and prognostic implications. TALL is 
known to have a better prognosis2 unless it is 
associated with other high risk factors like high 
WBC-count, mediastinal mass or CNS disease at 
diagnosis .10  
The frequency of TALL in Pakistani patients 
in this series was calculated to be 17.22%, which is 
different from that reported in other parts of Pakistan 
previously. In Rawalpindi, among all leukemia, 
TALL was reported to be 9.2% in 1990, which was 
much lower than that reported in other parts of the 
country e.g. in Lahore, TALL was reported to be 
29.1% in 1992.3 However, our study appears to be the 
best representative of the Pakistani population as it 
has the edge of being the most recent, having a 
greater sample size, collection of samples from all 
parts of Pakistan, a comprehensive panel of 
monoclonal antibodies and strict quality control 
validated by CAP. It is also interesting to note that 
one of our recent studies on T-cell Non-Hodgkin’s 
Lymphoma (T-NHL) showed a similar frequency i.e. 
22.2% among total NHLs in our population.11
Table-1:Demographic distribution of Acute Lymphoblastic Leukemia 
 Total Children (%) Adults (%) Males (%) Females (%) 
ALL 209 127(60.80%) 82(39.20%) 158(75.60%) 51(24.40%) 
TALL 36 18(50.0%) 18(50.0%) 25(69.40%) 11(30.60%) 
*p-value < 0.05 
Table-2: Reactivity of antigens in TALL patients  
 Children(%) Adults(%) Males(%) Females(%) Cases +ive Sensitivity 
CD3         06(33.3%) 08(44.4%) 10(40%) 04(36.4%) 14 38.8 % 
CD5 16(88.8%) 15(83.3%) 23(92%) 08(72.7%) 31 86.1 % 
CD7 17(94.4%) 17(94.4%) 24(96%) 10(90.9%) 34 94.4 % 
HLA-DR 02(11.1%) 02(11.1%) 02(8.0%) 02(18.2 %) 04 11.1 % 
CD13 01(5.5%) 02(11.1%) 00(0.0%) 03(27.3 %)* 03 08.3 % 
CD33 00(0.0%) 01(5.5%) 00(0.0%) 01(9.1%) 01 02.7 % 
*p-value < 0.05 
Table-3: Proportion of TALL in different regions of the world 
Region Country ALL %TALL 
Pakistan 209 17.2 
Thailand17 38 18.4 
Malaysia18 36 22.0 
South & South 
East Asia  
India28 45 17.0 
Middle East Saudi Arabia24 163 12.3 
Zimbabwe14 75 21.3 Africa 
Egypt19 124 50.0 
Italy20 2038 12.5 
Scotland21 498 18.1 
Netherlands22 91 19.8 
Germany26 1157 13.6 
Germany27 54 16.6 
Europe 
Yugoslavia39 54 11.1 
USA9  13.0 
Mexico13 402 09.4 
America 
Chile23 500 10.0 
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Figure-2. Light scatter and fluorescence dot plots of bone marrow from acute TALL. Note strong positivity of blasts for 
three T cell markers i.e., CD3, CD5 & CD7 and no reactivity with B-lymphoid, myeloid & HLA-DR. This phenotype is 
consistent with TALL. 
 
A higher percentage of males were affected 
than females in our studies as was expected due to 
previous reports.9,12-14 About 70% of the TALL 
patients were males. However, proportion of TALL 
was higher among females. In males the age group of 
16-21 was mostly affected while among females the 
most vulnerable group was found to be 5-10 years. In 
our study, ALL affected children more than the adults 
as is reported previously from Pakistan and abroad 
.4,12,14,15 Leukemia is the most common cancer among 
children in Pakistan.12,16 In US 2/3rd of the patients 
diagnosed with ALL are children.7 The correct 
diagnosis of phenotype of the leukemic cells is even 
more critical in children due to therapeutic 
implications as in US 80% of them are cured as 
compared to only 30%-40% of adults with ALL.7 
However, in our study proportion of TALL among 
adults was higher than that in children. Table 3 shows 
the proportion of TALL in different countries as 
reported in various studies. 
Review of literature (Table-3) shows the 
proportion of TALL with varied geographical 
location and socio-economic status. For instance, it is 
similar in Pakistan, India, Thailand and Malaysia17,18 
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forming an environmental belt of South & South East 
Asia. Very high proportions of TALL are reported in 
Egypt.19 From Middle East, in reports from Saudi 
Arabia and Oman, frequency of TALL is lower than 
the rest of the Asia and somewhat similar to that of 
western countries in Europe and America.9,13,20-27 This 
can be attributed to the similar economical conditions 
of these countries, as have been suggested by some 
previous reports.28 More studies are warranted to 
probe any association of the proportion of TALL 
with socio-economical conditions and geographical 
location. 
In our study, sensitivity of different markers 
was determined as the ratio of true positives to sum 
of true positives and false negatives. CD7 that turned 
out to be most sensitive (94.4%) is not totally reliable 
due to lack of specificity. In previous reports, it was 
demonstrated to cross react with 14% of non-TALL 
and 12.76% of BALL.12 CD5 also came out as a 
highly sensitive marker (positive in 86.1% of the 
cases). The high sensitivity of these markers in both 
children and adults is in accordance with the previous 
reports15,17 and are thus the most commonly used 
antigens for TALL diagnosis.28
Positivity of CD3 was 38.8% and like some 
previous studies12 wasn’t confirmed as the most 
sensitive marker, which is limited by the fact that it is 
uncommonly expressed on the surface of T lineage 
ALL and is almost always present abundantly in the 
cytoplasm of these cells.12,29,30 As in our analysis, the 
cells were not permeabalised; therefore antibodies 
only reacted with the surface CD3 antigens, thus 
resulting in a lower sensitivity. However, it is 
established as a relatively specific marker for 
TALL.12,31
HLA-DR cross-reacted with 11.1% of the 
TALL cases. CD13 and CD33 cross-reacted with 
8.3% and 2.7% cases of TALL. These cross-reacting 
antigens are usually expressed in AML but 
occasionally are also found in B or T lineage ALL. 
Almost same amount of myeloid aberrant expression 
has also been reported in other studies.17,32 Therefore 
they should be interpreted as strongly suggestive of 
myeloid leukemia only when are expressed in the 
absence of lymphoid associated antigens.33,34 Myeloid 
antigen positive ALL has been reported to respond 
better to the therapy, thus having a better prognosis 
than that of myeloid antigen negative ALL.8  
Lineage infidelity of the flowcytometric 
markers is an established fact. It refers to the 
phenotypic aberrations, which include asynchronous 
antigen expression, antigen over- expression and 
ectopic phenotype.32 This infidelity can be 
intralineage or interlineage35 as seen in our study, 
myeloid markers reacting with TALL cells. As 
mentioned earlier, no marker is ideally specific. 
Moreover, many leukemia cells exhibit loss of 
antigen specific to that particular lineage, therefore it 
is recommended that classification of leukemia is 
confirmed with antibody from a second CD cluster 
that is known to react principally with the suspected 
cell lineage. However if detection of the confirmatory 
maker fails, then the suspicion of the lineage 
proliferation still should not be excluded.12,29,36-38 
Moreover, markers of the other lineages are also 
applied to rule out the suspicions of their 
involvement in the disease. Hence, a panel of 
different antibodies is required to overcome the 
problem of lineage infidelity, thus, making a 
reasonably firm diagnosis.  
Checking the association of reactivity and 
cross-reactivity with different demographic 
parameters is a novel idea, which is tried in this 
study. This can be helpful in achieving separate 
panels of antibodies for cases of different 
demographic backgrounds. Since acute lymphoblastic 
leukemia are more difficult to study than the myeloid 
ones due to their heterogeneity, more extensive 
studies need to be done in this field to achieve a high 
yielding and reliable set of markers, not only for the 
diagnosis but also for the study of prognosis and 
minimal residual disease. 
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